The Study
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
This study is like a fair test where half the people got a new medicine and half got a fake pill, and then researchers saw who got sicker. Because they randomly picked who got what, we can guess the medicine probably helped—but we’re not 100% sure because we don’t know if everyone was blinded. It didn’t stop all problems, but it made them less likely.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
People with type 2 diabetes and kidney damage took a weekly shot called semaglutide. It helped their kidneys work better and lowered their chance of heart attacks, strokes, or dying early.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 568 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — for every 100 people treated, about 2–3 fewer would die or need dialysis over 3 years, which is a major benefit for high-risk patients.
- 2Semaglutide cut kidney/heart risks by 24%, heart death by 29%, and any death by 20%.
- 3It also slowed kidney function decline by 1.16 mL/min/1.73m² per year.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The New England journal of medicine
Year
2024
Authors
V. Perkovic, Katherine R. Tuttle, P. Rossing, Kenneth W Mahaffey, J. Mann, G. Bakris, F. Baeres, T. Idorn, H. Bosch‐Traberg, N. Lausvig, R. Pratley
Related Content
Claims (10)
In patients with type 2 diabetes and chronic kidney disease, semaglutide lowers the risk of kidney failure and related complications regardless of weight loss, and combining it with mineralocorticoid receptor antagonists does not significantly change its safety profile.
In patients with type 2 diabetes and chronic kidney disease, the medication semaglutide is associated with a lower chance of developing kidney failure and other kidney-related complications, even when accounting for changes in body weight.
Among adults with type 2 diabetes and chronic kidney disease, taking a weekly 1.0 mg dose of semaglutide is associated with a 29% lower risk of dying from cardiovascular causes compared to taking a placebo over approximately 3.4 years.
In adults with type 2 diabetes and moderate-to-severe chronic kidney disease, weekly injections of 1.0 mg semaglutide for about 3.4 years lower the risk of kidney failure, severe decline in kidney function, or death from kidney or heart causes by 24% compared to a placebo.
In adults with type 2 diabetes and chronic kidney disease, a weekly 1.0 mg dose of semaglutide slows the yearly loss of kidney function by 1.16 mL/min/1.73m² compared to a placebo.
In adults with type 2 diabetes and chronic kidney disease, taking 1.0 mg of semaglutide once a week results in a 20% lower risk of death from any cause compared to taking a placebo.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.